SCHEDULE: Bank of America Discloses 5.1% Stake in Novavax

Bank of America Corporation and its subsidiaries have reported a 5.1% beneficial ownership stake in Novavax Inc. common stock.

Summary

• Bank of America Corporation and its wholly-owned subsidiaries beneficially own 8,315,530 shares of Novavax Inc. common stock.
• This ownership represents 5.1% of Novavax's outstanding common stock.
• The beneficial ownership calculation is based on 162,498,995 outstanding shares of Novavax, as disclosed in the issuer's Form 10-Q on November 6, 2025, reporting share totals as of October 31, 2025.
• Bank of America holds shared voting power over 8,314,036 shares and shared dispositive power over 8,315,530 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Novavax.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive disclosure, primarily due to the confirmation of significant institutional ownership by a major financial entity, which can be interpreted as a vote of confidence or a strategic investment in Novavax.

Positives

• A significant institutional investor, Bank of America, holds a 5.1% stake in Novavax, indicating institutional interest in the company.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes by major financial entities. Bank of America's disclosure of a 5.1% stake in Novavax indicates continued institutional interest in the biotechnology sector, particularly in companies like Novavax which have been prominent in vaccine development.

Comparison to Industry Standards

• A 5.1% stake by a major financial institution like Bank of America is a substantial holding, often signaling a long-term investment or a significant position within diversified portfolios. This level of ownership is comparable to other large institutional holdings seen in mid-cap biotechnology companies, where institutional investors frequently take positions to gain exposure to specific therapeutic areas or growth potential.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder like Bank of America may provide a degree of confidence or stability, potentially influencing investor sentiment positively.
• Company Management: Awareness of a large institutional stake may influence strategic decisions, though Bank of America states its holding is not for influencing control.

Key Dates

Keywords

Novavax, Bank of America, NVAX, Schedule 13G, Institutional Ownership, Common Stock, Beneficial Ownership, SEC Filing